Table 3.
Comparison of mortality at day 28 between the HARP-2 cohort,14 HARP-2 matched cohort, and COVID-19 PHIND cohort
|
Total cohort |
Hypoinflammatory |
Hyperinflammatory |
||||
|---|---|---|---|---|---|---|
| n | Mortality | n | Mortality | n | Mortality | |
| HARP-2 | 539 | 132/539 (24%) | 353/539 (65%) | 59/353 (17%) | 186/539 (35%) | 73/186 (39%) |
| HARP-2 matched | 39 | 11/39 (28%) | 28/39 (72%) | 6/28 (21%) | 11/39 (28%) | 5/11 (45%) |
| COVID-19 | 39 | 17/39 (44%) | 31/39 (79%) | 12/31 (39%) | 8/39 (21%) | 5/8 (63%) |
Data are n or n/N (%). In HARP-2 and HARP-2 matched cohorts, the phenotypes were derived from the original latent class analysis studies. In the COVID-19 subset of the PHIND cohort, the phenotypes were derived using the parsimonious model using a probability cutoff of 0·274 (Youden index). HARP-2=Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction. PHIND=clinical evaluation of a point of care assay to identify PHenotypes IN the acute respiratory Distress syndrome.